Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period

in Arthritis and Rheumatism (2009, October), 60(number 10 (suppl.)), 313

The clinical and economic burden of nonadherence with osteoporosis medications

in Value in Health (2009, October), 12(7), 444

Cost-utility of denosumab for the treatment of postmenopausal osteoporotic women

in Osteoporosis International (2009, March), 20(S1), 5

Cost-utility of strontium ranelate for the prevention and treatment of postmenopausal osteoporotic women

in Osteoporosis International (2009, March), 20(S1), 129

Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year study

in Osteoporosis International (2009, March), 20(Suppl.1), 8

Association between changes in bone mineral density and fracture incidence in postmenopausal women receiving calcium and vitamin D : A 3-year study.

in Osteoporosis International (2009, March), 20(Suppl.1), 87-88

Effect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies.

in Osteoporosis International (2009, March), 20(Suppl.1), 18

Efficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne.

in Revue Médicale de Liège (2009), 64(10), 525-9

Numerous epidemiological approaches are used to demonstrate the efficacy of a new chemical entity. In postmenopausal osteoporosis, anti-fracture efficacy can be assessed through prospective, randomized ... [more ▼]

Numerous epidemiological approaches are used to demonstrate the efficacy of a new chemical entity. In postmenopausal osteoporosis, anti-fracture efficacy can be assessed through prospective, randomized controlled trials, meta-analyses or real-life setting studies. Intravenous ibandronate was recently marketed, with the aim of optimizing drug absorption and adherence to treatment. Furthermore, this new formulation avoids gastrointestinal side effects and constrains linked to the oral intake of the medication. Spinal anti-fracture efficacy of IV ibandronate derives from a non-inferiority bridging study, using surrogate endpoints, i.e., bone mineral density and biochemical markers of bone turnover, compared to the oral daily formulation, previously registered for the treatment of osteoporosis in Europe. Coherent results from two separate meta-analyses have suggested that the non-vertebral anti-fracture efficacy of IV ibandronate is similar to that observed with oral, daily and weekly bisphosphonates. Similarly, a recent real-life setting study, based on claims from an US database, suggests that hip fractures are reduced, with IV ibandronate, to the same extend as they are with oral bisphosphonates. Notwithstanding, those results should probably be confirmed in an European setting, before being extrapolated, in daily practice, to the Belgian population. [less ▲]

Effets du sulfate de chondroitine sur les indices d'utilité de santé chez des sujets gonarthrosiques et analyses économiques préliminaires.

in Revue du Rhumatisme (2009), 76

Analyses coût-efficacité du sulfate de glucosamine chez des patients gonarthrosiques : comparaison avec le paracétamol.

in Revue du Rhumatisme (2009), 76